Overexpression of ERBB3 has been shown to be associated with short survival of primary glioblastoma and is more frequent (up to 62%) in recurrent gliomas [31,32,44], suggesting that high ERBB3 activity may be involved with tumor aggressiveness and resistance to chemotherapy. Here, ERBB3 is linked to glioma.